Safety and Efficacy of Cethrin® in Adult Subjects With Acute Cervical Spinal Cord Injury

NCT ID: NCT00610337

Last Updated: 2014-01-17

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL

Brief Summary

This is a multicenter, randomized, double-blind, placebo-controlled, Phase IIb study to be conducted in North America and Europe and will include male and female subjects with acute cervical SCI, 18 to 62 years of age, who receive clinical trial material (CTM) within 72 hours of injury.

This study is being undertaken to evaluate and confirm the safety and efficacy of CETHRIN®. This adaptive study has been designed to efficiently identify the safest and most effective dose in Phase IIb which will be evaluated in a future Phase III study. Given the current lack of effective treatments for SCI, an improvement in motor ability or activities of daily living in these subjects would be a great advancement in the treatment of SCI.

Conditions

Acute Cervical Spinal Cord Injury

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

1

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: PROCEDURE

Spinal decompression surgery without administration of Cethrin® BA-210

2

1mg Cethrin®

Group Type: EXPERIMENTAL

Cethrin® (BA-210)

Intervention Type: DRUG

Intraoperative epidural administration during spinal decompression surgery

3

3mg Cethrin®

Group Type: EXPERIMENTAL

Cethrin® (BA-210)

Intervention Type: DRUG

Intraoperative epidural administration during spinal decompression surgery

4

6mg Cethrin®

Group Type: EXPERIMENTAL

Cethrin® (BA-210)

Intervention Type: DRUG

Intraoperative epidural administration during spinal decompression surgery

5

12mg Cethrin®. Administration of this dose is dependent on data from lower doses.

Group Type: EXPERIMENTAL

Cethrin® (BA-210)

Intervention Type: DRUG

Intraoperative epidural administration during spinal decompression surgery

6

18mg Cethrin®. Administration of this dose is dependent on data from lower doses.

Group Type: EXPERIMENTAL

Cethrin® (BA-210)

Intervention Type: DRUG

Intraoperative epidural administration during spinal decompression surgery

Interventions

Cethrin® (BA-210)

Intraoperative epidural administration during spinal decompression surgery

Intervention Type: DRUG

placebo

Spinal decompression surgery without administration of Cethrin® BA-210

Intervention Type: PROCEDURE

Other Intervention Names

Cethrin®

Eligibility Criteria

Inclusion Criteria

1. Ability to understand the requirements of the study, provide informed consent, agree to the study restrictions, and agree to return for the required assessments

2. Males or females, 18 through 62 years of age, inclusive

3. AIS Grade A, complete injury with the ability to obtain accurate baseline assessment

4. Motor neurological level of C5, C6, or C7

5. Subjects with acute cervical SCI scheduled to receive decompression/stabilization surgery

6. Must be willing and able to participate in study procedures and assessments

7. Must be medically stable

8. If of childbearing potential, women must agree to either of the following for the duration of the 12-month trial: (a) abstinence, or (b) if sexually active, to use one of the following methods of birth control: barrier with spermicide, intrauterine device, birth control hormones, or surgical sterilization

9. Must provide witnessed verbal authorization for use and disclosure of protected health information (PHI)

Exclusion Criteria

1. Subjects who have participated in a clinical trial involving investigational medications, devices or procedures within 30 days before administration of CTM

2. Subjects who require the use of mechanical ventilation

3. Females with a positive serum pregnancy test

4. Females who are breastfeeding

5. Preexisting SCI

6. Subjects who are unable to receive study medication within 72 hours of injury

7. Subjects with peripheral nerve injury, brachial plexus injury, or multifocal SCI

8. Subjects with injuries that prevent a comprehensive ASIA assessment

9. Complete spinal cord transection

10. Acute SCI because of gun shot or knife wound

11. Subjects who are mentally or medically unstable, or are otherwise unlikely to complete the trial in the judgment of the investigator

12. Subjects who present with history of symptomatic cervical spondylotic myelopathy

13. Subjects with moderate to severe traumatic brain injury with a Glasgow Coma Scale score of less than 14

14. History of multiple sclerosis or other neuromuscular disorder

15. History of an adverse reaction to a fibrin sealant or its human or bovine components

16. Clinically significant neurological, cardiac, respiratory, hepatic, or renal disease

17. History of cancer (except for basal cell carcinoma)

18. Hemophilia or other bleeding abnormality

19. Ankylosing spondylitis

20. Use of insulin therapy to control diabetes mellitus within 6 months of SCI

21. Known immunodeficiency, including human immunodeficiency virus or use of immunosuppressive or cancer chemotherapeutic drugs

22. Body mass index (BMI) of ≥40 kg/m2 at screening (Appendix B includes a table for height and weight to calculate BMI)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 62 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

BioAxone BioSciences, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

ALSE-C-01

Identifier Type: -

Identifier Source: org_study_id